课题基金 / 基金详情

LIPITOR/EZETIMIBE EFFICACY IN AN ALTERNATE DAY REGIMEN (LEADR)

LIPITOR/EZETIMIBE EFFICACY IN AN ALTERNATE DAY REGIMEN (LEADR)
隔日治疗方案中立普妥/依泽替米贝的疗效 (LEADR)
批准号:
7375363
负责人:
WILLIAM Bradford LAWSON
金额:
$0.04万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

WILLIAM Bradford LAWSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if the addition of Zetia to Lipitor in an alternate day dosing manner will lower the levels of LDL cholesterol (bad cholesterol) more than Lipitor itself.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GEN-RED
  • 批准号:
    7951430
  • 项目类别:
  • 资助金额:
    $2.13万
  • 财政年份:
    2009
  • 负责人:
    WILLIAM Bradford LAWSON
  • 依托单位:
GEN BD
  • 批准号:
    7607818
  • 项目类别:
  • 资助金额:
    $15.46万
  • 财政年份:
    2007
  • 负责人:
    WILLIAM Bradford LAWSON
  • 依托单位:
GEN-RED
  • 批准号:
    7607834
  • 项目类别:
  • 资助金额:
    $9.61万
  • 财政年份:
    2007
  • 负责人:
    WILLIAM Bradford LAWSON
  • 依托单位:
ETHICS
  • 批准号:
    7378692
  • 项目类别:
  • 资助金额:
    $0.13万
  • 财政年份:
    2006
  • 负责人:
    WILLIAM Bradford LAWSON
  • 依托单位:
国内基金
海外基金
Ezetimibe 靶向三阴性乳腺癌脂肪酸合成限速 酶 ACC 的抗肿瘤作用及机制研究
  • 批准号:
    Y24H200006
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    王燕忠
  • 依托单位: